AHA Coding Clinic® for ICD-10-CM and ICD-10-PCS - 2025 Issue 1; Section X – New Technology
Administration of Emapalumab-lzsg
In table XW0, Introduction of Anatomical Regions, substance values M emapalumab-lzsg Anti-IFNy monoclonal antibody, and N tarlatamab-dlle, were added to the body part values 3 Peripheral Vein and 4 Central Vein.Body Part Approach Device/Substance/Technology Qualifier 3 Peripheral Vein 4 Central Vein 3 Percutaneous M Emapalumab-lzsg Anti-IFNy Monoclonal Antibody N Tarlatamab-dlle Antineoplastic A New Technology Group 10 Emapalumab-Izsg is an interferon gamma (IFNy)-blocking antibody that is indicated in the treatment of adult and pediatric patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.Talaramab-dlle is a bispecific T-cell engager that...
Subscribe or sign in to view the full article.
Article Overview
This premium coding article covers a table update in an inpatient procedure code set and provides a brief clinical overview of two biologic/oncologic therapies mentioned in the update. It is relevant to coding professionals who need to track how new substance values are incorporated into anatomical region and access-related table structures, as well as readers seeking a high-level understanding of the therapies referenced. The article also notes the general treatment areas associated with the therapies, without providing detailed coding guidance in this public summary.
Why This Topic Matters
Updates to procedure coding tables can affect how newly recognized substances are represented in coding workflows and reference materials. Staying current helps coding and revenue cycle professionals align documentation review and code set maintenance with published table changes.
Article Sections
-
Table XW0 update
This section describes a table revision involving body part values, approach context, and added substance values. It presents the coding-table setting for the update without detailing selection rules.
-
Clinical context for the referenced therapies
This section gives a brief overview of the therapies named in the table update and the general conditions they are associated with. It serves as background context for the coding reference.
What You Will Learn
- How the article frames a coding table update related to administration procedures
- What general clinical areas are associated with the therapies mentioned
- How the article situates the update within a broader procedure coding context
- Why maintaining current table references matters for coding workflows
Who Should Read This
- Medical coders
- Coding auditors
- Revenue cycle professionals
- Clinical documentation specialists
- Health information management staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com